Switch theme
Sign up to access all valuation multiples
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
1992
5.5K+
LTM Revenue $878M
Last FY EBITDA $381M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tianjin Pharma has a last 12-month revenue (LTM) of $878M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Tianjin Pharma achieved revenue of $1.0B and an EBITDA of $381M.
Tianjin Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tianjin Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $878M | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $487M | XXX | $489M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $381M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 38% | XXX | XXX | XXX |
| EBIT | $268M | XXX | $119M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $233M | XXX | $309M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tianjin Pharma's stock price is CNY 30 (or $4).
Tianjin Pharma has current market cap of CNY 22.8B (or $3.2B), and EV of CNY 21.4B (or $3.0B).
See Tianjin Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.2B | XXX | XXX | XXX | XXX | $0.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tianjin Pharma has market cap of $3.2B and EV of $3.0B.
Tianjin Pharma's trades at 2.9x EV/Revenue multiple, and 7.8x EV/EBITDA.
Equity research analysts estimate Tianjin Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tianjin Pharma has a P/E ratio of 13.6x.
See valuation multiples for Tianjin Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBIT | 11.1x | XXX | 25.1x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.6x | XXX | 10.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 26.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTianjin Pharma's last 12 month revenue growth is -19%
Tianjin Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Tianjin Pharma's rule of 40 is -4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tianjin Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tianjin Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -19% | XXX | -15% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -4% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tianjin Pharma acquired XXX companies to date.
Last acquisition by Tianjin Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Tianjin Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tianjin Pharma founded? | Tianjin Pharma was founded in 1992. |
| Where is Tianjin Pharma headquartered? | Tianjin Pharma is headquartered in China. |
| How many employees does Tianjin Pharma have? | As of today, Tianjin Pharma has 5.5K+ employees. |
| Is Tianjin Pharma publicy listed? | Yes, Tianjin Pharma is a public company listed on SHG. |
| What is the stock symbol of Tianjin Pharma? | Tianjin Pharma trades under 600329 ticker. |
| When did Tianjin Pharma go public? | Tianjin Pharma went public in 2001. |
| Who are competitors of Tianjin Pharma? | Similar companies to Tianjin Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tianjin Pharma? | Tianjin Pharma's current market cap is $3.2B |
| What is the current revenue of Tianjin Pharma? | Tianjin Pharma's last 12 months revenue is $878M. |
| What is the current revenue growth of Tianjin Pharma? | Tianjin Pharma revenue growth (NTM/LTM) is -19%. |
| What is the current EV/Revenue multiple of Tianjin Pharma? | Current revenue multiple of Tianjin Pharma is 3.4x. |
| Is Tianjin Pharma profitable? | Yes, Tianjin Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
